HK1206393A1 - 用於診斷和治療廣泛性發育障礙的組合物和方法 - Google Patents
用於診斷和治療廣泛性發育障礙的組合物和方法Info
- Publication number
- HK1206393A1 HK1206393A1 HK15106693.0A HK15106693A HK1206393A1 HK 1206393 A1 HK1206393 A1 HK 1206393A1 HK 15106693 A HK15106693 A HK 15106693A HK 1206393 A1 HK1206393 A1 HK 1206393A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diagnosis
- compositions
- treatment
- methods
- developmental disorder
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261606935P | 2012-03-05 | 2012-03-05 | |
PCT/US2013/029201 WO2013134315A1 (en) | 2012-03-05 | 2013-03-05 | Compositions and methods for diagnosis and treatment of pervasive developmental disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206393A1 true HK1206393A1 (zh) | 2016-01-08 |
Family
ID=49117277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15106693.0A HK1206393A1 (zh) | 2012-03-05 | 2015-07-14 | 用於診斷和治療廣泛性發育障礙的組合物和方法 |
Country Status (9)
Country | Link |
---|---|
US (4) | US20150023949A1 (zh) |
EP (1) | EP2823063A4 (zh) |
JP (3) | JP2015517801A (zh) |
KR (1) | KR20140140069A (zh) |
CN (1) | CN104364393A (zh) |
AU (1) | AU2013230045A1 (zh) |
CA (1) | CA2866407A1 (zh) |
HK (1) | HK1206393A1 (zh) |
WO (1) | WO2013134315A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
WO2016040725A1 (en) | 2014-09-11 | 2016-03-17 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
EP3440705A4 (en) | 2016-04-01 | 2019-11-13 | INTEL Corporation | TRANSISTOR CELLS COMPRISING A DEEP INTERCONNECTION HOLE COVERED WITH DIELECTRIC MATERIAL |
US10650621B1 (en) | 2016-09-13 | 2020-05-12 | Iocurrents, Inc. | Interfacing with a vehicular controller area network |
CN106885858A (zh) * | 2017-03-10 | 2017-06-23 | 方雷 | 一种高效的痕量临床病人样本的高通量全蛋白组学定量分析方法 |
CN107312846A (zh) * | 2017-07-12 | 2017-11-03 | 北京赛尔维康生物医学科技有限公司 | Capg和ptgis基因在制备脊柱侧弯检测试剂盒中的应用 |
CN109212226B (zh) * | 2018-09-06 | 2021-04-06 | 中国人民解放军联勤保障部队第九〇四医院 | 预测急性高山病发病风险的血浆蛋白标志物及其在制备诊断ams易感性试剂盒中的应用 |
CN109239334A (zh) * | 2018-09-10 | 2019-01-18 | 吉林大学 | 建立时间分辨荧光免疫层析法检测MxA试剂盒 |
EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
WO2020215043A1 (en) * | 2019-04-19 | 2020-10-22 | Yale University | Advanced glycation end-product breaking biocatalysts |
KR102158009B1 (ko) * | 2019-06-13 | 2020-09-21 | 고려대학교 산학협력단 | 주의력 결핍/과잉행동장애 진단용 마커로서의 14-3-3γ의 용도 |
CN112442527B (zh) * | 2019-08-27 | 2022-11-11 | 深圳市英马诺生物科技有限公司 | 孤独症诊断试剂盒、基因芯片、基因靶点筛选方法及应用 |
EP4348265A2 (en) * | 2021-05-25 | 2024-04-10 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Diagnosis of autism spectrum disorder by multiomics platform |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2207033B1 (en) * | 2004-04-15 | 2014-06-18 | University of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
GB0419124D0 (en) * | 2004-08-27 | 2004-09-29 | Proteome Sciences Plc | Methods and compositions relating to Alzheimer's disease |
WO2006079092A2 (en) * | 2005-01-24 | 2006-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for modeling cell signaling systems by means of bayesian networks |
EP1840574A1 (en) * | 2006-03-30 | 2007-10-03 | Institut Pasteur | Use of the alpha chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases |
US20090117562A1 (en) * | 2007-04-09 | 2009-05-07 | Valerie Wailin Hu | Method and kit for diagnosing Autism using gene expression profiling |
WO2009105718A1 (en) * | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
US8173369B2 (en) * | 2008-05-15 | 2012-05-08 | The Regents Of The University Of California | Peripheral gene expression biomarkers for autism |
WO2010056982A2 (en) * | 2008-11-17 | 2010-05-20 | The George Washington University | Compositions and methods for identifying autism spectrum disorders |
US20120178637A1 (en) * | 2009-07-07 | 2012-07-12 | Abbott Laboratories | Biomarkers and methods for detecting alzheimer's disease |
WO2011031803A1 (en) * | 2009-09-08 | 2011-03-17 | Nodality, Inc. | Analysis of cell networks |
WO2011112961A1 (en) * | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns |
MY181093A (en) * | 2011-03-02 | 2020-12-17 | Berg Llc | Interrogatory cell-based assays and uses thereof |
CN104487842B (zh) * | 2012-05-22 | 2017-09-08 | 博格有限责任公司 | 用于鉴别药物诱导毒性标志物的基于细胞的探询式分析 |
-
2013
- 2013-03-05 WO PCT/US2013/029201 patent/WO2013134315A1/en active Application Filing
- 2013-03-05 AU AU2013230045A patent/AU2013230045A1/en not_active Abandoned
- 2013-03-05 CA CA2866407A patent/CA2866407A1/en not_active Abandoned
- 2013-03-05 JP JP2014561056A patent/JP2015517801A/ja active Pending
- 2013-03-05 US US14/383,450 patent/US20150023949A1/en not_active Abandoned
- 2013-03-05 KR KR20147028035A patent/KR20140140069A/ko not_active Application Discontinuation
- 2013-03-05 CN CN201380022420.3A patent/CN104364393A/zh active Pending
- 2013-03-05 EP EP13758001.5A patent/EP2823063A4/en not_active Withdrawn
-
2015
- 2015-07-14 HK HK15106693.0A patent/HK1206393A1/zh unknown
-
2017
- 2017-12-04 US US15/830,982 patent/US20180275146A1/en not_active Abandoned
-
2018
- 2018-04-05 JP JP2018072819A patent/JP2018153184A/ja active Pending
-
2019
- 2019-02-14 US US16/275,944 patent/US20190242909A1/en not_active Abandoned
-
2020
- 2020-08-14 JP JP2020137031A patent/JP2020193986A/ja active Pending
-
2021
- 2021-06-11 US US17/346,152 patent/US20220137070A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2015517801A (ja) | 2015-06-25 |
EP2823063A4 (en) | 2016-02-10 |
CN104364393A (zh) | 2015-02-18 |
EP2823063A1 (en) | 2015-01-14 |
US20190242909A1 (en) | 2019-08-08 |
KR20140140069A (ko) | 2014-12-08 |
US20150023949A1 (en) | 2015-01-22 |
US20220137070A1 (en) | 2022-05-05 |
WO2013134315A1 (en) | 2013-09-12 |
AU2013230045A1 (en) | 2014-09-11 |
JP2020193986A (ja) | 2020-12-03 |
CA2866407A1 (en) | 2013-09-12 |
JP2018153184A (ja) | 2018-10-04 |
US20180275146A1 (en) | 2018-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206393A1 (zh) | 用於診斷和治療廣泛性發育障礙的組合物和方法 | |
HK1212273A1 (zh) | 治療和診斷黑素瘤 | |
EP2890808A4 (en) | DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES | |
EP2892558A4 (en) | VISTA MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
EP2890815A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
HK1200739A1 (zh) | 用於治療癌症的診斷方法和組合物 | |
ZA201408056B (en) | Compositions and methods for the treatment of mucositis | |
HK1201045A1 (zh) | 用於腫瘤診斷和治療的組合物和方法 | |
IL234606B (en) | Innovative methods and compounds for the treatment of diseases | |
IL239374B (en) | Preparations and methods for treating brain tumors | |
HK1215794A1 (zh) | 用於治療疾病的同種異體自噬體富集組合物 | |
HK1202053A1 (zh) | 肝臟狀況的治療 | |
ZA201501038B (en) | Treatment of wax | |
EP2928456A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
SG11201504201RA (en) | Purification of x-ray contrast agents | |
FI3473276T3 (fi) | Tekniikoita paiseiden hoitoon | |
GB201218263D0 (en) | Treatment of autism | |
IL233740A0 (en) | Treatment of liver diseases | |
GB201221118D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201208048D0 (en) | Treatment of digestive disorder | |
GB201206325D0 (en) | Methods of treatment |